ALPHAMAB-B

9966
5.6601.48% ( -0.085 )
Delay Closed: Nov 16, 16:08:11

Overview

ALPHAMAB-B (9966)

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment...

Open
5.545
High
5.670
Low
5.280
Prev. Close
5.745
Volume
1.22M
Turnover
6.69M
Avg Price
5.473
Bid/Ask Ratio
-14.29%
Amplitude
6.79%
52wk High
12.200
Volume Ratio
0.78
Turnover Ratio
0.13%
52wk Low
5.280
HK Mkt Cap
5.46B
Market CapHKD
5.46B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.210
EPSDynamic
-0.0965
EPSStatic
--
BVPS
2.00
P/B
2.84
HK Shares
965.15M
Dividend YieldTTM
--
DividendTTM
--
Shares
965.15M
Min lot size
1,000
Currency
HKD

ALPHAMAB-B Analyst Rating

View more

Forecast & Rating

Oct 12, 2026
Price forecast
HK$9.6069.62%
Forecast & RatingBuy
2analysts
  • Strong buy50.00%
  • Buy50.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Alphamab Oncology (9966.HK) reversed early losses to close at HK$5.635, down 1.91%, after sliding to HK$5.285 intraday, a fresh 52-week low, as a confirmed death cross and follow-through selling from the prior day's trough pushed the morning session from the HK$5.745 open to the day's low within half an hour, before afternoon buying recovered most of the gap on 1.22 million shares worth HK$6.69 million. Fundamentals offer little offset: Q2 2026 revenue fell 10.5% year on year to HK$156.6 million, the net loss widened nearly threefold to HK$23.37 million and EPS was -HK$0.0242. The stock is down 40.92% year to date, 53.6% below its 19 April peak of HK$12.20, and trades under both its MA20 of HK$6.37 and MA60 of HK$7.52. Offsetting items include new CFO David Ng, repeated buybacks and FDA clearance of JSKN021 for trials. Though a 2.84x price-to-book against negative earnings shows profitability has yet to turn.

  2. Nov, 12

    Alphamab Oncology (9966.HK) reversed an early rise and fell as much as 6.4% intraday before paring losses, closing at HK$6.000, down 2.44% from HK$6.150, after Q2 2026 revenue fell 10.5% year on year to HK$156.6 million and net loss widened 297.68% to HK$23.4 million. The stock touched HK$6.190 at 09:35 BJ, then slid to HK$5.755 at 14:31 BJ, a fresh 52-week low, before afternoon buying lifted it back toward the open. Net margin was -14.9% and EPS -HK$0.0242, alongside PE -28.58, PB 3.01 and a HK$5.79 billion market value; the price sits below MA20 (6.477) and MA60 (7.602), is down 37.37% year to date and 50.82% below the 52-week high of HK$12.20, with 955,000 shares and HK$5.66 million turnover. Though repeated share buyback disclosures, FDA clearance for a JSKN021 Phase I trial, first-patient dosing in the JSKN033 Phase III cervical cancer study and the appointment of David Ng as CFO offered some support into the close.

  3. Nov, 9

    Alphamab Oncology (9966.HK) closed up 1.36% at HK$6.34 after a spike-and-fade session: it touched HK$6.60 at 09:54 BJ before sliding to HK$6.28 by 13:12 BJ, with only 558,000 shares and HK$3.58 million traded (0.06% turnover) and a HK$6.418 average price above the close. The company remains loss-making: Q2 2026 revenue of HK$156.6 million fell 10.5% yoy, the net loss widened 297.7% yoy to HK$23.4 million, net margin stood at -14.92%, EPS at -HK$0.0242 and PB at 3.18x. The stock is down 33.82% YTD and 48.03% below its 19 April 52-week high of HK$12.20, though still 8.01% above the 2 November low of HK$5.87, while trading below both MA20 of HK$6.619 and MA60 of HK$7.706. Liquidity is thin, so the intraday swing reflects sparse flow more than conviction.

  4. Nov, 6

    Shares reversed early strength: the stock opened at HK$6.660, the session high, then slid to HK$6.215 by 13:25 BJ and closed at HK$6.255, down 6.01% on HK$5.07 million turnover, unwinding the roughly 7% rally booked after the FDA cleared JSKN021 for a Phase I trial. The move sat against a still-lossmaking profile, with Q2 revenue of HK$156.6 million down 10.5% year on year and a net loss of HK$23.37 million. Buybacks of 446,000 shares for about HK$2.74 million between November 2 and 5, first-patient dosing in JSKN033's Phase III cervical cancer study, and ESMO presentations covering KN026 and JSKN003 did not stem the decline. At HK$6.255 the stock trades below its 20-day MA of HK$6.67 and 60-day MA of HK$7.742, is down 34.71% year to date and 48.73% below the 52-week high of HK$12.20, and sits just 6.56% above the HK$5.87 low, with market capitalization of HK$6.04 billion on a 3.14 price-to-book. Though the ADC pipeline continues to advance.

  5. Nov, 4

    FDA clearance of an IND for JSKN021 brought in buyers, and Alphamab Oncology (9966.HK) traced a dip-and-rebound session: it slid to HK$6.120 in the morning, then pushed to HK$6.600 at 14:09 BJ before closing at HK$6.545, about 6.9% above the intraday low on 1.064 million shares. The news flow has been dense: buybacks of 230,000 and 160,000 shares on 2 and 3 November, a first patient dosed in the Phase III cervical cancer trial of JSKN033, and ESMO 2026 disclosures of JSKN003 plus two Phase III KN026 (anbenitamab) datasets as LBA oral presentations, including a 54% reduction in risk of progression or death in Phase III breast cancer. Though Q2 2026 revenue of HK$156.6 million was down 10.5% year on year, with a net loss of HK$23.37 million and a -14.9% net margin and PE at -31.2, the stock still trades below its MA20 of HK$6.806 and MA60 of HK$7.81, down 31.68% year to date and 46.92% below the 52-week high of HK$12.33, only 11.5% above the 2 November low of HK$5.87.

News